Urinary Tract Infection Management

Diagnosis

The diagnosis of UTIs can be based on symptoms such as new onset dysuria, urinary frequency, urgency to urinate, nocturia, and suprapubic discomfort, with urinalysis showing moderate to large leukocytes and positive nitrites, as recommended by the American Urological Association and European Urology guidelines 1, 2
Urine culture should be obtained before starting antibiotics to identify the causative organism and its antibiotic susceptibility pattern, as recommended by the Infectious Diseases Society of America 3
Significant bacteriuria is defined as ≥50,000 CFUs/mL of a single uropathogen in an appropriately collected specimen, or pure growth of 250,000 CFUs/mL of a uropathogen with urinalysis showing bacteriuria or pyuria, as defined by the Infectious Diseases Society of America 4
Bacterial counts of >10,000 CFU/mL of a uropathogen are considered a fundamental confirmatory diagnostic test for urinary tract infections in adults, as defined by the Infectious Diseases Society of America 5

First-line therapy options include nitrofurantoin: 5-day course, trimethoprim-sulfamethoxazole (TMP-SMX): 3-day course (if local resistance <20%), and fosfomycin: single 3g dose, as recommended by the American Urological Association 1
Fosfomycin is highly effective for treating urinary tract infections caused by ESBL-producing bacteria, with high-certainty evidence supporting intravenous fosfomycin for complicated UTIs and oral fosfomycin as an effective single-dose treatment for uncomplicated UTIs 6
Fluoroquinolones should be reserved for patients with pyelonephritis cases (when susceptibility is known), complicated UTIs with resistant organisms, or patients with documented history of resistant pathogens, as recommended by the Infectious Diseases Society of America 7
Short-course therapy (3-5 days) is as effective as longer courses with fewer adverse events, according to the American College of Physicians 7

The following levofloxacin dosing is recommended for patients with renal impairment:

Creatinine Clearance	Recommended Levofloxacin Dosing
≥50 mL/min	500 mg once daily
26-49 mL/min	500 mg once daily
10-25 mL/min	250 mg once daily

Aminoglycosides, such as gentamicin, tobramycin, and amikacin, have a high risk of nephrotoxicity and ototoxicity, and should be avoided unless no suitable alternatives are available, as recommended by the KDIGO guidelines and the American Journal of Kidney Diseases 8, 9, 10
Novel β-lactam agents, such as Ceftazidime/avibactam and Meropenem/vaborbactam, are recommended as first-line treatment for carbapenem-resistant K. pneumoniae 16
Alternative options for treating carbapenem-resistant K. pneumoniae include Imipenem/relebactam and Cefiderocol 16

The treatment duration for complicated UTI is 10-14 days 17
If bacteremia is present, the Clinical Infectious Diseases society recommends extending treatment to 4-6 weeks 17
The Clinical Infectious Diseases society recommends considering S. aureus bacteremia if S. aureus is present in urine, and obtaining blood cultures before starting antibiotics 17

Maintaining adequate hydration throughout the day is recommended for UTI prevention in diabetic women, as suggested by the European Urology and Journal of Urology associations 15, 2
Voiding after sexual intercourse is recommended to prevent UTIs in diabetic women, as suggested by the European Urology association 15
Increasing fluid intake is strongly recommended for reducing recurrent UTI (rUTI) risk, with strong evidence supporting its effectiveness, as stated by the European Urology guidelines 2
Methenamine hippurate is strongly recommended for women without urinary tract abnormalities, as suggested by the European Urology association 2
Controlling blood glucose is essential for UTI prevention in diabetic women, along with vaginal estrogen replacement therapy and methenamine hippurate as first-line non-antibiotic preventive measures, as recommended by the European Urology association 15, 2

Asymptomatic bacteriuria should not be treated except in pregnant women and patients undergoing invasive urinary procedures, as recommended by the American Urological Association 1
The Infectious Diseases Society of America strongly recommends against screening for or treating asymptomatic bacteriuria in diabetic patients, as recommended by the Infectious Diseases Society of America 18
For pregnant women, the European Association of Urology recommends screening for and treating asymptomatic bacteriuria with standard short-course treatment or single-dose fosfomycin trometamol, as recommended by the European Association of Urology 2

The American College of Physicians recommends avoiding fluoroquinolones in elderly patients due to adverse effects 19
The Clinical Infectious Diseases society recommends avoiding treatment of asymptomatic bacteriuria in the elderly unless preparing for urologic procedures 18
The Clinical Infectious Diseases society suggests distinguishing between delirium and UTI in elderly patients, and looking for specific urinary symptoms or signs of systemic infection before triggering antibiotic treatment 18
Patients with heart failure risk should be monitored when using fosfomycin, as 8.6% developed heart failure in the FOREST trial 6
Administering antibiotics after hemodialysis sessions is crucial to avoid premature removal of the drug, as recommended by the American Thoracic Society, facilitating directly observed therapy and ensuring appropriate drug levels 20
The American Diabetes Association recommends calculating GFR before prescribing certain medications using online calculators to ensure safe treatment, particularly for diabetic patients with potential renal impairment, and optimizing blood glucose to reduce the risk of UTI and slow the progression of nephropathy in diabetic patients, as recommended by the American Diabetes Association 21

The Infectious Diseases Society of America recommends removing any indwelling urinary catheters if present to prevent further infection 22
Rapid testing strategies to identify specific resistance mechanisms are strongly recommended to guide appropriate antibiotic therapy for severe or multidrug-resistant infections 16